Surgifort is the first FDA-approved human milk-based fortifier specifically designed for term infants recovering from ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses how IMU-856 could support the challenges of gluten-free diets and cross-contamination risks for celiac disease.

Aspargo Labs uses a proprietary technology platform to reformulate oral medication to liquid doses. CEO and chairman Michael ...

Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well ...

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...

Biopharmas and global agencies are now prioritizing initiatives and innovations to drive speed across product development ...

Unconfirmed reports suggest that a popular flu vaccine educational campaign has come to an end.

John Arena, interim president of global pharma services at Cencora, discusses how new technologies are shortening timelines.

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

John Arena, interim president of global pharma services at Cencora, discusses the importance of engaging with partners as ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...